Search results
Results from the WOW.Com Content Network
The French pharmaceutical company Sanofi says it has reached an agreement to resolve 4,000 cases in the U.S., in which plaintiffs are linking the discontinued heartburn drug Zantac — and its ...
Zantac was first marketed in 1981, [7] and it was described in 1989 as "one of the most expensive drugs on the market", [8] and "the world's biggest-selling prescription drug". [9] Addiction to taking it ("a habit") was how some of its users described Zantac. [ 10 ]
No reliable studies link Zantac use to cancer, Cheffo said, a view shared by all the defendants. Instead, he said, plaintiffs rely on a finding that Zantac's active ingredient, ranitidine, can ...
Delaware's highest court said on Tuesday it will hear an appeal by GSK and other drugmakers seeking to end more than 70,000 lawsuits claiming discontinued heartburn drug Zantac caused cancer. GSK ...
(Reuters) -A Delaware judge has allowed more than 70,000 lawsuits over discontinued heartburn drug Zantac to go forward, ruling that expert witnesses can testify in court that the drug may cause ...
(Reuters) -Pfizer has agreed to settle more than 10,000 lawsuits about cancer risks related to the now discontinued heartburn drug Zantac, Bloomberg News reported on Wednesday, citing people ...
France, Germany, European Union Polyneuropathy. [3] Natalizumab (Tysabri) 2005–2006 US Voluntarily withdrawn from US market because of risk of Progressive multifocal leukoencephalopathy (PML). Returned to market July 2006. Nefazodone: 2004 Europe, Australia, New Zealand and Canada [35] [36] [37]
First approved in 1983, Zantac became the world's best-selling medicine in 1988 and one of the first to top $1 billion in annual sales. It was originally marketed by a forerunner of GSK and later ...